R1 Therapeutics raises $77.5M to advance AP306 in dialysis-related hyperphosphatemia
R1 Therapeutics secures $77.5 million to push AP306, a hyperphosphatemia treatment, into Phase 2b for dialysis patients, with a potential late- decade market launch.